Centessa Pharmaceuticals plc Logo

Centessa Pharmaceuticals plc

Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.

CNTA | US

Overview

Corporate Details

ISIN(s):
US1523091007
LEI:
Country:
United States of America
Address:
3RD FLOOR, ALTRINCHAM, CHESHIRE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients with unmet medical needs. The company leverages a data-driven Research & Development model to advance a portfolio of innovative assets. Its lead program is a potential best-in-class orexin receptor 2 (OX2R) agonist being developed for the treatment of sleep-wake disorders. The company's pipeline also includes programs targeting other conditions, such as hemophilia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Centessa Pharmaceuticals plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Centessa Pharmaceuticals plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Centessa Pharmaceuticals plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR
PureTech Health plc Logo
A clinical-stage biotherapeutics firm developing new medicines for devastating diseases.
United States of America PRTC
PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America QNTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.